short telomere cancers are now geron's focus. this focus was not the case two short years ago. it took some time for the new chief executive to become familiar with geron's plight, but chip was able to take action by disrobing the company of its dead weight (i.e.,OPC1,1005). although these decisions came as a surprise to the market, especially the closing of the LONG telomere breast cancer trial, the steps taken were necessary in order to move on the innovative telomerase activity inhibitor — GRN163L.
the geron corporation has its work to do. the company needs clinical data to substantiate the inference that imetelstat effectively blocks telomerase activity in cancers with short telomeres. this of course is the key to geron's value. the company needs to collect and collate imetelstat trial data from which chief medical officer kelsey can draw convincing conclusions that will allow chip to negotiate a partnership or, most likely, a buyout agreement with big pharma.